Ariad Pharmaceuticals, Inc. (ARIA) - Financial and Strategic SWOT Analysis Review

Date: April 19, 2016
Pages: 56
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A11463219BCEN
Leaflet:

Download PDF Leaflet

Ariad Pharmaceuticals, Inc. (ARIA) - Financial and Strategic SWOT Analysis Review
Ariad Pharmaceuticals, Inc. (ARIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Ariad Pharmaceuticals Inc (Ariad) focuses on the discovery, development and marketing of small-molecule oncology therapies. Its products are indicated to treat chronic and acute leukemia, lung cancer and other difficult to treat cancers. The company’s lead product, Iclusig (ponatinib) is indicated for the treatment of chronic myeloid leukemia (CML). Ariad’s pipeline portfolio comprises three promising molecules including Iclusig, a novel oral multi-targeted kinase inhibitor; Brigatinib, an anaplastic lymphoma kinase inhibitor; and AP32788, a drug candidate, for the treatment of patients with NSCLC with specific mutations in the EGFR or HER2 kinases. Additionally, the company's research and development efforts are focused on exploring cell-signaling pathways and discovering new molecules that interfere with the aberrant signaling pathways of cells and aid in treatment of cancers. Ariad is headquartered in Massachusetts, the US.

Ariad Pharmaceuticals, Inc. Key Recent Developments

Mar 29, 2016: ARIAD Announces Reduction in Workforce as Part of Ongoing Company-Wide Strategic Review
Mar 22, 2016: ARIAD Reports Inducement Grant to New Chief Financial Officer
Mar 11, 2016: ARIAD Announces Appointment of Manmeet S. Soni as Chief Financial Officer
Feb 23, 2016: ARIAD Reports 2015 Financial Results, Provides 2016 Product Revenue Guidance and Outlines Company Progress
Jan 15, 2016: ARIAD Reports Inducement Grant to New Chief Executive Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

    Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

    Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

    Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

    Note: Some sections may be missing if data is unavailable for the company
  • SECTION 1 - ABOUT THE COMPANY

    Ariad Pharmaceuticals, Inc. - Key Facts
    Ariad Pharmaceuticals, Inc. - Key Employees
    Ariad Pharmaceuticals, Inc. - Key Employee Biographies
    Ariad Pharmaceuticals, Inc. - Major Products and Services
    Ariad Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data
    Ariad Pharmaceuticals, Inc., Pipeline Products by Therapy Area
    Ariad Pharmaceuticals, Inc., Pipeline Products by Development Phase
    Ariad Pharmaceuticals, Inc. - History
    Ariad Pharmaceuticals, Inc. - Company Statement
    Ariad Pharmaceuticals, Inc. - Locations And Subsidiaries
    Head Office
    Other Locations & Subsidiaries

    SECTION 2 – COMPANY ANALYSIS

    Ariad Pharmaceuticals, Inc. - Business Description
    Ariad Pharmaceuticals, Inc. - Corporate Strategy
    Ariad Pharmaceuticals, Inc. - SWOT Analysis
    SWOT Analysis - Overview
    Ariad Pharmaceuticals, Inc. - Strengths
    Strength - Research and Development Activities
    Strength - Lead Candidate: Iclusig
    Ariad Pharmaceuticals, Inc. - Weaknesses
    Weakness - History of Operating Losses
    Ariad Pharmaceuticals, Inc. - Opportunities
    Opportunity - Orphan Drug Designation: Ponatinib
    Opportunity - Market Potential: Iclusig
    Opportunity - Product Pipeline
    Ariad Pharmaceuticals, Inc. - Threats
    Threat - Competitive Pressures
    Threat - Intellectual Property Risk
    Threat - Dependence on Third Parties
    Ariad Pharmaceuticals, Inc. - Key Competitors

    SECTION 3 – COMPANY FINANCIAL RATIOS

    Financial Ratios - Capital Market Ratios
    Financial Ratios - Annual Ratios
    Performance Chart
    Financial Performance
    Financial Ratios - Interim Ratios
    Financial Ratios - Ratio Charts

    SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

    Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
    Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
    Ariad Pharmaceuticals, Inc., Recent Deals Summary

    SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

    Mar 29, 2016: ARIAD Announces Reduction in Workforce as Part of Ongoing Company-Wide Strategic Review
    Mar 22, 2016: ARIAD Reports Inducement Grant to New Chief Financial Officer
    Mar 11, 2016: ARIAD Announces Appointment of Manmeet S. Soni as Chief Financial Officer
    Feb 23, 2016: ARIAD Reports 2015 Financial Results, Provides 2016 Product Revenue Guidance and Outlines Company Progress
    Jan 15, 2016: ARIAD Reports Inducement Grant to New Chief Executive Officer
    Jan 10, 2016: ARIAD Announces Election of Alex Denner as Chairman of the Board of Directors
    Dec 18, 2015: ARIAD Names Paris Panayiotopoulos as Its President and Chief Executive Officer
    Nov 03, 2015: ARIAD Reports Third Quarter 2015 Financial Results and Progress on Strategic Objectives
    Aug 05, 2015: ARIAD Reports Second Quarter 2015 Financial Results and Progress on Strategic Objectives
    May 07, 2015: ARIAD Reports First Quarter 2015 Financial Results and Progress on Strategic Objectives

    SECTION 6 – APPENDIX

    Methodology
    Ratio Definitions
    About GlobalData
    Contact Us
    Disclaimer

    LIST OF TABLES

    Ariad Pharmaceuticals, Inc., Key Facts
    Ariad Pharmaceuticals, Inc., Key Employees
    Ariad Pharmaceuticals, Inc., Key Employee Biographies
    Ariad Pharmaceuticals, Inc., Major Products and Services
    Ariad Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area
    Ariad Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage
    Ariad Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase
    Ariad Pharmaceuticals, Inc., History
    Ariad Pharmaceuticals, Inc., Subsidiaries
    Ariad Pharmaceuticals, Inc., Key Competitors
    Ariad Pharmaceuticals, Inc., Ratios based on current share price
    Ariad Pharmaceuticals, Inc., Annual Ratios
    Ariad Pharmaceuticals, Inc., Interim Ratios
    Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
    Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
    Ariad Pharmaceuticals, Inc., Recent Deals Summary
    Currency Codes
    Capital Market Ratios
    Equity Ratios
    Profitability Ratios
    Cost Ratios
    Liquidity Ratios
    Leverage Ratios
    Efficiency Ratios

    LIST OF FIGURES

    Ariad Pharmaceuticals, Inc., Pipeline Products by Therapy Area
    Ariad Pharmaceuticals, Inc., Pipeline Products by Development Phase
    Ariad Pharmaceuticals, Inc., Performance Chart (2011 - 2015)
    Ariad Pharmaceuticals, Inc., Ratio Charts
    Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
    Ariad Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
    Skip to top


    Ask Your Question

    Ariad Pharmaceuticals, Inc. (ARIA) - Financial and Strategic SWOT Analysis Review
    Company name*:
    Contact person*:
    Phone/fax*:
    Email*:
    Request invoice
    Your enquiry:
    Please click on a Check Box below to confirm you are not a robot: